Animal and immunizations of Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
BALB/c mice (an albino, laboratory mice strain) between 6 to 8 weeks old were placed into groups of n = 7 or 8. The mice were injected intramuscularly with 0.01 to 10 microg dosage of saRNA encoding SARS-CoV-2 spike protein encapsulated in LNP vaccine. An electroplated plasmid DNA vaccine was used as a positive control while saRNA encoding the rabies glycoprotein (RABV) in pABOL vaccine was used as a negative control. The mice were immunized on week 0, given a booster shot on week 4, and euthanized on week 6, where their spleen was collected and processed to single cells for assay use. Their serum samples were also collected every two weeks.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Vectors of Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
In vitro transcription of RNA of Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
Formulation of saRNA of Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
Animal and immunizations of Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
Identification of immunogenicity of Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
Recovered COVID-19 patient samples of Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice